Eli Lilly and Company

Patients with early Alzheimer’s disease, caregivers and doctors who may have been reluctant to try Eli Lilly’s Kisunla (donanemab) due to the risk of amyloid-related imaging abnormalities (ARIA) with

Frontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,

The outlook for biopharmaceutical company financings has grown increasingly grim in 2025 as drug developer valuations remain challenged by various macroeconomic and industry-specific concerns. New dat

Apogee Therapeutics has posted positive data from its long-acting antibody, APG777, that showed it reduced symptoms of the inflammatory skin condition atopic dermatitis in a 123-patient Phase II study